Selective inhibitor of SUMO-activating enzyme "Subasumstat" (TAK-981) identified to inhibit the growth of MCL cells when grown in stromal conditions and induced tumor regression in MCL-PDX model via inhibiting OXPHOS pathway and thus overcoming BTKi resistance mechanism. Here, IBTK is linked to neoplasm.